Several other equities analysts have also recently weighed in on the stock. ValuEngine cut shares of Corcept Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, February 4th. Zacks Investment Research cut shares of Corcept Therapeutics from a hold rating to a sell rating and set a $14.00 target price for the company. in a research note on Tuesday, February 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Corcept Therapeutics presently has an average rating of Hold and a consensus price target of $16.50.
CORT opened at $13.34 on Tuesday. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of 18.53 and a beta of 1.25. The company has a fifty day moving average of $12.77 and a 200 day moving average of $13.33. Corcept Therapeutics has a fifty-two week low of $9.55 and a fifty-two week high of $17.48.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Featured Article: What is the Current Ratio?
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.